PL2176664T3 - Ccr4 jako marker nowotworowy - Google Patents

Ccr4 jako marker nowotworowy

Info

Publication number
PL2176664T3
PL2176664T3 PL08806315T PL08806315T PL2176664T3 PL 2176664 T3 PL2176664 T3 PL 2176664T3 PL 08806315 T PL08806315 T PL 08806315T PL 08806315 T PL08806315 T PL 08806315T PL 2176664 T3 PL2176664 T3 PL 2176664T3
Authority
PL
Poland
Prior art keywords
ccr4
cancer marker
marker
cancer
Prior art date
Application number
PL08806315T
Other languages
English (en)
Inventor
Frances Balkwill
Violet Slettenaar
Julia Wilson
Yaohe Wang
Tiziana Schioppa
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2176664(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of PL2176664T3 publication Critical patent/PL2176664T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08806315T 2007-09-18 2008-09-18 Ccr4 jako marker nowotworowy PL2176664T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
PCT/GB2008/003160 WO2009037454A2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target
EP08806315.1A EP2176664B1 (en) 2007-09-18 2008-09-18 Ccr4 as cancer marker

Publications (1)

Publication Number Publication Date
PL2176664T3 true PL2176664T3 (pl) 2014-04-30

Family

ID=38670078

Family Applications (3)

Application Number Title Priority Date Filing Date
PL08806315T PL2176664T3 (pl) 2007-09-18 2008-09-18 Ccr4 jako marker nowotworowy
PL12182790.1T PL2533047T3 (pl) 2007-09-18 2008-09-18 Ccr4 jako cel terapeutyczny dla nowotworu
PL12183760T PL2535716T3 (pl) 2007-09-18 2008-09-18 Marker nowotworowy i cel terapeutyczny

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL12182790.1T PL2533047T3 (pl) 2007-09-18 2008-09-18 Ccr4 jako cel terapeutyczny dla nowotworu
PL12183760T PL2535716T3 (pl) 2007-09-18 2008-09-18 Marker nowotworowy i cel terapeutyczny

Country Status (11)

Country Link
US (2) US9134293B2 (pl)
EP (3) EP2535716B1 (pl)
JP (2) JP5774309B2 (pl)
AU (1) AU2008300413B2 (pl)
CA (1) CA2699702C (pl)
DK (3) DK2533047T3 (pl)
ES (3) ES2588507T3 (pl)
GB (1) GB0718167D0 (pl)
PL (3) PL2176664T3 (pl)
RU (2) RU2529797C2 (pl)
WO (1) WO2009037454A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US9229004B2 (en) 2008-09-26 2016-01-05 The General Hospital Corporation Methods for detecting and treating cancer
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
US20130095473A1 (en) * 2010-06-14 2013-04-18 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
EP2771488B1 (en) * 2011-10-24 2018-03-28 SignalChem Lifesciences Corporation Carbonic anhydrase ix-related markers and use thereof
CN103998429B (zh) 2011-12-01 2016-12-07 凯莫森特里克斯股份有限公司 作为ccr(4)拮抗剂的取代的苯胺类
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
UA119973C2 (uk) * 2013-11-06 2019-09-10 Янссен Байотек, Інк. Антитіло до ссl17
US10155818B2 (en) 2014-05-28 2018-12-18 Agenus Inc. Anti-GITR antibodies and methods of use thereof
EP3201631B1 (en) * 2014-10-01 2021-05-26 SphingoTec GmbH Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
CN107624071A (zh) * 2015-04-17 2018-01-23 诺福泰克公司 肺癌治疗方法
JP7089470B2 (ja) 2015-12-02 2022-06-22 アジェナス インコーポレイテッド 抗体およびその使用方法
EP3626269A4 (en) * 2017-05-19 2021-03-03 Shingo Maeda METHOD FOR INFILTRATION OF REGULATORY T-CELLS USING CCR4 INHIBITION AND METHOD FOR TREATMENT OF NEOPLASTIC DISEASES IN DOGS

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
WO1994021814A1 (en) * 1993-03-19 1994-09-29 The Johns Hopkins University Antibodies and assays for determining mutations in the apc gene
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
AU3607301A (en) 2000-03-03 2001-09-12 Kyowa Hakko Kogyo Kk Gene recombinant antibody and its fragment
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
EP1578341A4 (en) 2000-10-11 2005-09-28 Tularik Inc MODULATION OF THE CCR4 FUNCTION
AU2002223619B2 (en) 2000-10-18 2006-08-24 Schering Ag Use of antiprogestins for the induction of apoptosis in a cell
JP2004535157A (ja) * 2001-02-28 2004-11-25 プロテイン デザイン ラブス， インコーポレイテッド ケモカイン受容体と疾患
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
NZ531069A (en) 2001-08-10 2007-01-26 Topigen Pharma Inc Methods for modulating viral infection of cells by modulating a binding interaction between a CCR1, CCR2, CCR3, CCR4, CCR5 and/or CCR8 receptor and a surface protein of the virus
AU2002338015B8 (en) 2001-08-31 2008-03-20 Kyowa Kirin Co., Ltd. Human CDR-grafted antibodies and antibody fragments thereof
JPWO2004007472A1 (ja) 2002-07-10 2005-11-17 小野薬品工業株式会社 Ｃｃｒ４アンタゴニストおよびその医薬用途
AU2003291549A1 (en) 2002-11-15 2004-06-15 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
JP2007524362A (ja) * 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US7732442B2 (en) * 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
WO2005035582A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Ｃｃｒ４に特異的に結合する抗体組成物
CA2548454C (en) 2003-12-04 2013-12-31 Kyowa Hakko Kogyo Co., Ltd. Medicament comprising recombinant antibody against chemokine receptor ccr4
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
PL2135949T3 (pl) 2006-02-14 2013-03-29 Noxxon Pharma Ag Kwasy nukleinowe wiążące MCP-1
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Also Published As

Publication number Publication date
RU2014128513A (ru) 2016-02-10
US20160223572A1 (en) 2016-08-04
EP2533047A1 (en) 2012-12-12
US9134293B2 (en) 2015-09-15
DK2535716T3 (en) 2017-02-13
EP2535716B1 (en) 2016-11-02
DK2176664T3 (da) 2014-01-20
EP2535716A3 (en) 2013-03-13
AU2008300413B2 (en) 2014-09-11
JP2015212703A (ja) 2015-11-26
EP2535716A2 (en) 2012-12-19
ES2612690T3 (es) 2017-05-18
EP2533047B1 (en) 2016-05-11
WO2009037454A2 (en) 2009-03-26
JP5774309B2 (ja) 2015-09-09
EP2176664A2 (en) 2010-04-21
US20100278844A1 (en) 2010-11-04
PL2533047T3 (pl) 2016-11-30
RU2529797C2 (ru) 2014-09-27
JP2010539508A (ja) 2010-12-16
RU2010123921A (ru) 2011-12-20
CA2699702A1 (en) 2009-03-26
US10261099B2 (en) 2019-04-16
ES2588507T3 (es) 2016-11-03
EP2176664B1 (en) 2013-11-06
DK2533047T3 (en) 2016-08-22
WO2009037454A3 (en) 2009-05-07
JP6234967B2 (ja) 2017-11-22
CA2699702C (en) 2018-03-06
PL2535716T3 (pl) 2017-06-30
ES2443541T3 (es) 2014-02-19
AU2008300413A1 (en) 2009-03-26
GB0718167D0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
PL2176664T3 (pl) Ccr4 jako marker nowotworowy
EP2079385A4 (en) MAMMARY MARKER
GB0700534D0 (en) Composition
GB0717101D0 (en) Tumour marker
ZA201002072B (en) Topical composition
GB0724412D0 (en) Marker
ZA201003055B (en) Topical composition
AU320442S (en) Marker
GB0822155D0 (en) Marker
GB0706343D0 (en) Composition
GB0705885D0 (en) Composition
GB0702446D0 (en) Composition
GB0703719D0 (en) Composition
GB0706739D0 (en) Composition
GB0704651D0 (en) Composition
EP2187216A4 (en) NEW LIVER CANCER MARKER
GB0718496D0 (en) Markers
EP2174998A4 (en) WAX CHALK
GB0707972D0 (en) Composition
GB0703654D0 (en) Sterimatic dose marker
GB0710559D0 (en) Composition
GB0704659D0 (en) Composition
GB0701817D0 (en) Marker
GB2444433B (en) Marker
GB2436401B (en) Marker